Pharma industry reputation gains, says Harris Interactive

Share this article:
It seems corporate reputation is countercyclical for pharmas, as well. The drug industry was the only sector to see appreciable gains in public perception from 2007 to 2008, according to Harris Interactive. The industry posted its highest rating in five years as financial services firms and automakers displaced pharmas in the dregs of public esteem alongside tobacco.

The good news is that the pharmaceutical sector is now less loathed than energy/utilities, airlines, insurance, automotive, tobacco and financial services. The bad news: with positive ratings up five percentage points to 31%, the drug industry isn't exactly in clover.

Still, in a year when negative perceptions of corporate America jumped 17 points to 88%, it's significant, said Dr. Robert Fronk, SVP, reputation strategy at Harris Interactive, who notes that the industry's positive rankings have hovered in the mid-20s for years.

“I do believe that the industry is beginning to get some credit,” said Fronk, “both for changes in behavior, in how companies are thinking about reputation, as well as communications.”

For its Reputation Quotient study, Harris Interactive first asks a pool of respondents – 6,587 for this year's study -- what companies have the best and worst reputation in order to determine its list of the most visible companies. The data firm then asks a larger group, of 20,483 for 2008, to rate those firms. Among pharmas, this year's 16 most visible firms included only Johnson & Johnson, a company better known for its consumer products than its drug and device businesses. That's a good sign, said Fronk, since pharmas that have made the short list in years past have done so mainly through negative publicity.

Among sectors, financial services tied with tobacco, as a mere 11% of respondents gave it a positive rating. Positive perception of the automotive industry plunged 22 points to 16%.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...